[en] Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western world. It is characterized by a high dependency on interactions with the surrounding immune landscape, highlighting its suitability for immune-mediated therapeutic interventions. We recently revealed that the cytokine IL-27 exerts a strong anti-tumor role in CLL through a T-cell-mediated mechanism.
Pagano, Giulia ✱; Tumor Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg ; Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
MOUSSAY, Etienne ✱; University of Luxembourg ; Tumor Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg
PAGGETTI, Jerome ✱; University of Luxembourg ; Tumor Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg
✱ Ces auteurs ont contribué de façon équivalente à la publication.
Co-auteurs externes :
no
Langue du document :
Anglais
Titre :
Interleukin-27 tackles immunosuppression in chronic lymphocytic leukemia.
Luxembourg National Research Fund (FNR) and Fondation Cancer, Luxembourg Fonds National de la Recherche Scientifique (FNRS)-Télévie
Subventionnement (détails) :
This work was supported by grants from the Luxembourg National Research Fund (FNR) and Fondation Cancer, Luxembourg to EM and JP (C20/BM/14582635 and C20/BM/14592342) and from Fonds National de la Recherche Scientifique (FNRS)-Télévie to IFB and GP (7.4501.18, 7.4529.19, 7.6518.20, and 7.6603.21).
Conlon KC, Miljkovic MD, Waldmann TA. Cytokines in the treatment of cancer. J Interferon Cytokine Res. 2019; 39 (1): 6–3. doi: 10.1089/jir.2018.0019.
Fabbi M, Carbotti G, Ferrini S. Dual roles of IL-27 in cancer biology and immunotherapy. Mediators Inflamm. 2017; 2017: 3958069. doi: 10.1155/2017/3958069.
Wierz M, Janji B, Berchem G, Moussay E, Paggetti J High-dimensional mass cytometry analysis revealed microenvironment complexity in chronic lymphocytic leukemia. Oncoimmunology. 2018; 7 (8): e1465167. doi: 10.1080/2162402X.2018.1465167.
Wierz M, Pierson S, Guyonnet L, Viry E, Lequeux A, Oudin A, Niclou SP, Ollert M, Berchem G, Janji B, Guérin C. Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia. Blood. 2018; 131 (14): 1617–1621. doi: 10.1182/blood-2017-06-792267.
Cid LL, Leong JK, Botana IF, Paul Y, Wierz M, Floerchinger A, Gonder S, Pagano G, Chazotte M, Bestak K, Schifflers CT. High-dimensional single-cell definition of CLL T cells identifies galectin-9 as novel immunotherapy target. bioRxiv. 2022. doi: 10.1101/2022.12.15.519719.
Mantovani A, Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature. 2008; 454 (7203): 436–444. doi: 10.1038/nature07205.
Pagano G, Botana IF, Wierz M, Roessner PM, Ioannou N, Zhou X, Al-Hity G, Borne C, Gargiulo E, Gonder S, Qu B. Interleukin-27 potentiates CD8+ T-cell-mediated anti-tumor immunity in chronic lymphocytic leukemia. Haematologica. 2023. doi: 10.3324/haematol.2022.282474.
Zorzoli A, Di Carlo E, Cocco C, Ognio E, Ribatti D, Ferretti E, Dufour C, Locatelli F, Montagna D, Airoldi I, et al. Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg−/− mice. Clin Cancer Res. 2012; 18 (6): 1630–1640. doi: 10.1158/1078-0432.CCR-11-2432.
Schoppmeyer R, Zhao R, Cheng H, Hamed M, Liu C, Zhou X, Schwarz EC, Zhou Y, Knörck A, Schwär G, et al. Human profilin 1 is a negative regulator of CTL mediated cell-killing and migration. Eur J Immunol. 2017; 47 (9): 1562–1572. doi: 10.1002/eji.201747124.
